Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Canada And China Renew Plan Of Action For Cooperation In Health For 2009-2011
The Honourable Leona Aglukkaq, Minister of Health, and Dr. Chen Zhu, Minister of Health for the People"s Republic of China, today signed a Plan of Action for continued cooperation between the two countries on health priorities of mutual concern. The signing ceremony followed discussions among senior Canadian and Chinese health officials and experts on a range of health issues, including strengthening and reform of health-care systems, primary health care and food safety.
generic viagra online
Scientists Find New Human HIV From Gorillas
Scientists who found a new human immunodeficiency virus (HIV) in a Cameroonian woman living in Paris, have discovered it is an unusual
News of the day
Some Groups Say Iowa HIV Transmission Law Worsens Stigma, Hinders Testing Efforts
Some Iowa groups are concerned that the state"s criminal HIV transmission law adds to the stigma associated with the virus and hampers testing efforts, and are urging lawmakers to revisit the law, the Iowa Independent reports. According to the Independent, criminal transmission of HIV is classified among the second-most serious felonies that can be committed in the state. Those that have been convicted under the law have been sentenced to a few months to several decades in prison. Former state Rep. Ed Fallon (D) who supported the 1998 law, said, "It seems to me that since it is now 11, almost 12, years later, it wouldn"t be [a] bad time to take a look at it again," adding that "surely [there] are some tweaks or changes that the legislature could consider relevant to this law, especially with all the new knowledge we have of the disease" (Waddington, 7/1).
Oncology

Novavax Completes Enrollment Of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial

Novavax, Inc. (Nasdaq: NVAX) announced that enrollment has been completed in the second Phase II clinical trial of its trivalent virus-like particle (VLP) seasonal influenza vaccine. This Phase IIa randomized, placebo-controlled study is evaluating a VLP vaccine against the H3N2, H1N1, and B influenza strains that circulated in the 2008-2009 influenza season. This clinical trial represents another step in the development of Novavax"s VLP seasonal influenza vaccine, allowing further evaluation of safety and immunogenicity of a broad range of vaccine doses against a new set of influenza strains. As announced in December of 2008, the first Phase II study evaluated a trivalent VLP vaccine against the seasonal influenza strains that circulated in the 2005-2006 influenza season. Specifically, this new study is evaluating the safety and immunogenicity of the 2008-2009 influenza vaccine in approximately 220 healthy adults between the ages of 18 and 49 years. Subjects have received a single injection of either a placebo or the VLP vaccine at doses of 15 mcg or 60 mcg per strain. The results of this study will be used to help select a dose for further evaluation in a clinical trial involving adults 65 years of age and older later this year and in a subsequent Phase III efficacy study. "Enrollment of this second Phase II clinical trial represents another important developmental milestone for our VLP seasonal influenza vaccine program," said Dr. Rahul Singhvi, President and CEO of Novavax. "This study provides the opportunity to evaluate the safety and immunogenicity of our VLP vaccine against a new set of influenza strains, further strengthening our growing clinical database for VLP-based influenza vaccines. The completion of enrollment keeps us on track for having top line data for the 2008-2009 vaccine in the third quarter of this year and for selecting a dose for a Phase II trial in older adults later this year." About Novavax Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Forward Looking Statement Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax"s product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials; dependence on the efforts of third parties; competition for clinical res and patient enrollment from drug candidates in development by other companies with greater res and visibility; and risks that we may lack the financial res and access to capital to fund our operations including further clinical trials. Novavax, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009